Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

Arthritis & Rheumatism

Volumn 36, Issue 12, 1993, Pages 1681-1690

  Elliott, Michael J ^a,b   Maini, Ravinder N ^a,b   Feldmann, Marc ^a,b   Long‐Fox, Alice ^a,b   Charles, Peter ^a,b   Katsikis, Peter ^a,b   Brennan, Fionula M ^a,b   Walker, Jean ^a,b   Bijl, Hanny ^a,b   Ghrayeb, John ^a,b   Woody, James N ^a,b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; CHIMERA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CHIMERA; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T; TUMOR NECROSIS FACTOR;

EID: 0027438710     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780361206     Document Type: Article

References (42)

1. Taking mortality in rheumatoid arthritis seriously: predictive markers, socioeconomic status and comorbidity
2. Long‐term outcome of treating rheumatoid arthritis: results after 20 years
3. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study
4. Anti‐CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells
5. Immunological effects of high dose administration of anti‐CD4 antibody in rheumatoid arthritis patients
6. Treatment of rheumatoid arthritis with an anti‐CD4 monoclonal antibody
7. Monoclonal antibody treatment in rheumatoid arthritis: the clinical and immunological effects of a CD7 monoclonal antibody
8. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M‐T151: clinical results and immunopharmacologic effects in an open study, including repeated administration
9. Therapeutic use of monoclonal anti‐CD4 antibody in rheumatoid arthritis
10. Humanised monoclonal antibody therapy for rheumatoid arthritis
11. Rheumatoid arthritis: its present and future
12. Interleukin‐1 activity in the synovial fluid of patients with rheumatoid arthritis
13. Interleukin‐1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL‐1α
14. Localization of tumor necrosis factor α in synovial tissues and at the cartilage–pannus junction in patients with rheumatoid arthritis
15. Excessive production of interleukin 6‐B cell stimulatory factor‐2 in rheumatoid arthritis
16. Cytokines in chronic inflammatory arthritis, II: Granulocytemacrophage colony‐stimulating factor in rheumatoid synovial effusions
17. Detection of interleukin‐8 biologic activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin‐8 mRNA by isolated synovial cells
18. Detection of transforming growth factor‐b̃ in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures
19. Transforming growth factor‐b̃1 in rheumatoid synovial membrane and cartilage‐pannus junction
20. High rate of HLA class II mRNA synthesis in rheumatoid arthritis joints and its persistence in culture: down regulation by recombinant interleukin‐2
21. Inhibitory effects of TNFα antibodies on synovial cell interleukin‐1 production in rheumatoid arthritis
22. Expression of granulocyte–macrophage colony‐stimulating factor (GM‐CSF) in rheumatoid arthritis: regulation by tumour necrosis factor‐α
23. Enhanced expression of tumour necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints
24. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage–pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α
25. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis
26. Anti‐tumour necrosis factor ameliorates joint disease in murine collagen‐induced arthritis
27. Cytokine production in the rheumatoid joint: implications for treatment
28. TNFα: a pivotal role in rheumatoid arthritis?
29. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
30. The assessment of disease activity in rheumatoid arthritis using a multivariate analysis
31. Therapeutic criteria in rheumatoid arthritis
32. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis
33. A simplified twenty‐eight‐joint quantitative articular index in rheumatoid arthritis
34. Stanford health assessment questionnaire modified to assess disability in British patients with rheumatoid arthritis
35. Analysis of improvement in individual rheumatoid arthritis patients treated with disease‐modifying antirheumatic drugs, based on the findings in patients treated with placebo
36. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor‐tumour necrosis factor from human monocytes
37. Evidence that tumour necrosis factor has an important role in antibacterial resistance
38. Antibodies to cachectin‐tumour necrosis factor reduce interleukin‐1b̃ and interleukin‐6 appearance during lethal bacteremia
39. Synovium as a source of interleukin‐6 in vivo: contribution to local and systemic manifestations of arthritis
40. Preliminary report on cytokine determination in human synovial fluids: a consensus study of the European Workshop for Rheumatology Research
41. Immunotherapy of rheumatic diseases: practice and prospects
42. Immunotherapy and other novel therapies